<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760847</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY20201373</org_study_id>
    <nct_id>NCT04760847</nct_id>
  </id_info>
  <brief_title>Intermittent Fasting for Pancreatitis</brief_title>
  <acronym>IF Panc</acronym>
  <official_title>Intermittent Fasting as a Primary Means for Improving Quality of Life for Acute and Chronic Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to compare intermittent fasting with a standard diet approach&#xD;
      for improving the quality of life related to your pancreas disease. Our hope is to improve&#xD;
      your symptoms and prevent you from needing to go into the hospital for pancreas-related&#xD;
      issues.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fasting is a classic means for religious discipline, yet recently regaining favor in the&#xD;
      medical landscape. Numerous studies have come forth, both in animals and humans outlining the&#xD;
      benefit of intermittent fasting (IF) on various disease states and longevity. Though a&#xD;
      relatively complex cellular process, fasting for at least 8-12 hours has been shown to lead&#xD;
      to fatty acid release from a patient's adipose storage. These fatty acids then shuttle to the&#xD;
      liver, where they are converted to ketones such as beta-hydroxybutyrate and acetoacetate.&#xD;
&#xD;
      Ketones are then utilized for energy sources in the heart, brain and skeletal muscle tissue.&#xD;
      The energy produced (ATP), then leads to increase in the cellular powerhouses, the&#xD;
      mitochondria and autophagy or cell recycling. This cellular recycling is one main way in&#xD;
      which IF has proven benefit for inflammatory conditions and in cancer care.&#xD;
&#xD;
      Furthermore, reductions in amino acids and glucose due to fasting and reliance on ketones as&#xD;
      energy, lead to down regulation of the mTOR pathway. Much is known regarding the mTOR&#xD;
      pathway. Down regulation of mTOR is associated with increased autophagy (as above), lower&#xD;
      protein and lipid synthesis, ribosome and lysosome creation (cell shuttles) and lowered&#xD;
      energy use.&#xD;
&#xD;
      Specific to the pancreas, mTOR down regulation has been shown to lower protein synthesis with&#xD;
      the pancreas, caused by cholecystokinin (CCK), a pancreas stimulating hormone.2 The effect of&#xD;
      this leads to lower pancreatic enzymes secretion. Inhibition of mTOR also lowers the&#xD;
      generation of fibroblasts, the scar-tissue cells within the pancreas, leading to less&#xD;
      scar-formation.3 Scar tissue formation is a vital part of morbidity and complications for&#xD;
      patients with chronic pancreatitis.&#xD;
&#xD;
      Pancreatic disease-modulation has also been evaluated in regard to the mTOR pathway.4 For&#xD;
      pancreatic cancer, rapamycin a mTOR inhibitor have been implicated as targets for&#xD;
      chemotherapy. Clinical trials have shown benefit for pancreatic cancer cases given rapamycin&#xD;
      in concert with other chemotherapeutic medications.5 For acute, chronic pancreatitis and&#xD;
      post-ERCP pancreatitis, mTOR is usually activated.6 In particular, blocking the mTOR pathway&#xD;
      can favor autophagy, limit cell death (apoptosis) and hence necrosis of the pancreas.&#xD;
      Necrosis in pancreatitis, leads to complex disease, possess a higher mortality, organ&#xD;
      failure, and can make the clinical course more complicated. Therefore, the mTOR pathway has&#xD;
      been implicated as a potential therapeutic target to ameliorate disease course and&#xD;
      severity.4,7,8 The purpose of this study is to evaluate IF as a means for limiting disease&#xD;
      severity with people who have recurrent acute pancreatitis and chronic pancreatitis. Our&#xD;
      hypothesis is that IF will improve pancreatic-disease related quality of life.1&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The control group will have 32 patients and the group undergoing IF will have 32 patients (for both recurrent acute and chronic pancreatitis); the randomization is 1:1; IF versus control. Sixty four subjects will be enrolled at UH for a total of 64 subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreas related Quality of Life Index (PANQALI)</measure>
    <time_frame>24 weeks</time_frame>
    <description>A pancreas related quality of life index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>24 weeks</time_frame>
    <description>standard score from 0-10 (0 no pain, 10 worst pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Morphine Equivalent Daily Dosing</measure>
    <time_frame>24 weeks</time_frame>
    <description>total dose of opiates taken converted into morphine in milligrams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient weight</measure>
    <time_frame>24 weeks</time_frame>
    <description>pounds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Body mass index</measure>
    <time_frame>24 weeks</time_frame>
    <description>pounds/inch squared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vitamin D 25-OH levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>levels of vitamin D 25-OH in nanograms/milliLiter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool pancreatic elastase levels</measure>
    <time_frame>24 weeks</time_frame>
    <description>stool elastatse level in micrograms/gram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmissions</measure>
    <time_frame>24 weeks</time_frame>
    <description>patient need to seek medical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay</measure>
    <time_frame>24 weeks</time_frame>
    <description>days requiring medical care</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Pancreatitis</condition>
  <condition>Pancreatitis, Acute</condition>
  <condition>Pancreatitis, Chronic</condition>
  <condition>Pancreas Disease</condition>
  <condition>Acute Recurrent Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Intermittent Fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Group A will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intermittent Fasting</intervention_name>
    <description>These subjects will will then receive information regarding intermittent fasting, which would include fasting for a 16-hour period each day, followed by ingestion of an appropriate number of calories for the remaining part of the day. See attached IF Quick Facts for details provided to the patient.</description>
    <arm_group_label>Intermittent Fasting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intermittent fasting</intervention_name>
    <description>These subjects will undergo standard caloric dietary guidance. Patients in group B will also be given the above information, though not be asked to intermittently fast</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age â‰¥ 18 year&#xD;
&#xD;
        Recurrent acute pancreatitis defined by greater than 2 episodes of pancreatitis, defined&#xD;
        by:&#xD;
&#xD;
        abdominal pain and either amylase or lipase &gt; 3 x the upper limit of normal, imaging&#xD;
        suggestive of, separated by time Anatomy of chronic pancreatitis defined by Rosemont&#xD;
        criterion9 or on imaging (CT, MRI) Pancreatic exocrine insufficiency defined by a&#xD;
        pancreatic elastase &lt; 200 ug/g stool10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Age &lt; 18 years Pregnant Patients Age &gt; 80 years Patients who cannot consent for themselves&#xD;
        Glycogen storage disease Insulinoma or hypoglycemic state Active alcohol abuse Alcohol&#xD;
        induced acute pancreatitis Gallstone induced acute pancreatitis Pancreatic solid neoplasm&#xD;
        Patients with diabetes Patients on beta blockers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaffer Mok</last_name>
    <phone>4404065500</phone>
    <email>Shaffer.Mok@UHhospitals.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Shaffer Mok, MD</last_name>
      <phone>440-406-5500</phone>
      <email>Shaffer.Mok@UHhospitals.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wassef W, DeWitt J, McGreevy K, Wilcox M, Whitcomb D, Yadav D, Amann S, Mishra G, Alkaade S, Romagnuolo J, Stevens T, Vargo J, Gardner T, Singh V, Park W, Hartigan C, Barton B, Bova C. Pancreatitis Quality of Life Instrument: A Psychometric Evaluation. Am J Gastroenterol. 2016 Aug;111(8):1177-86. doi: 10.1038/ajg.2016.225. Epub 2016 Jun 14.</citation>
    <PMID>27296943</PMID>
  </reference>
  <reference>
    <citation>Crozier SJ, Sans MD, Guo L, D'Alecy LG, Williams JA. Activation of the mTOR signalling pathway is required for pancreatic growth in protease-inhibitor-fed mice. J Physiol. 2006 Jun 15;573(Pt 3):775-86. Epub 2006 Apr 13.</citation>
    <PMID>16613881</PMID>
  </reference>
  <reference>
    <citation>Yang J, Waldron RT, Su HY, Moro A, Chang HH, Eibl G, Ferreri K, Kandeel FR, Lugea A, Li L, Pandol SJ. Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol. 2016 Oct 1;311(4):G675-G687. doi: 10.1152/ajpgi.00251.2016. Epub 2016 Sep 8.</citation>
    <PMID>27609771</PMID>
  </reference>
  <reference>
    <citation>Bellizzi AM, Bloomston M, Zhou XP, Iwenofu OH, Frankel WL. The mTOR pathway is frequently activated in pancreatic ductal adenocarcinoma and chronic pancreatitis. Appl Immunohistochem Mol Morphol. 2010 Oct;18(5):442-7. doi: 10.1097/PAI.0b013e3181de115b.</citation>
    <PMID>20661135</PMID>
  </reference>
  <reference>
    <citation>Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368.</citation>
    <PMID>20630061</PMID>
  </reference>
  <reference>
    <citation>Law R, Leal C, Dayyeh BA, Leise MD, Balderramo D, Baron TH, Cardenas A. Role of immunosuppression in post-endoscopic retrograde cholangiopancreatography pancreatitis after liver transplantation: a retrospective analysis. Liver Transpl. 2013 Dec;19(12):1354-60. doi: 10.1002/lt.23758.</citation>
    <PMID>24115362</PMID>
  </reference>
  <reference>
    <citation>Ji L, Li L, Qu F, Zhang G, Wang Y, Bai X, Pan S, Xue D, Wang G, Sun B. Hydrogen sulphide exacerbates acute pancreatitis by over-activating autophagy via AMPK/mTOR pathway. J Cell Mol Med. 2016 Dec;20(12):2349-2361. doi: 10.1111/jcmm.12928. Epub 2016 Jul 15.</citation>
    <PMID>27419805</PMID>
  </reference>
  <reference>
    <citation>Wu XM, Ji KQ, Wang HY, Zhao Y, Jia J, Gao XP, Zang B. MicroRNA-339-3p alleviates inflammation and edema and suppresses pulmonary microvascular endothelial cell apoptosis in mice with severe acute pancreatitis-associated acute lung injury by regulating Anxa3 via the Akt/mTOR signaling pathway. J Cell Biochem. 2018 Aug;119(8):6704-6714. doi: 10.1002/jcb.26859. Epub 2018 Apr 25. Retraction in: J Cell Biochem. 2021 Nov;122 Suppl 1:S107.</citation>
    <PMID>29693276</PMID>
  </reference>
  <reference>
    <citation>Conwell DL, Lee LS, Yadav D, Longnecker DS, Miller FH, Mortele KJ, Levy MJ, Kwon R, Lieb JG, Stevens T, Toskes PP, Gardner TB, Gelrud A, Wu BU, Forsmark CE, Vege SS. American Pancreatic Association Practice Guidelines in Chronic Pancreatitis: evidence-based report on diagnostic guidelines. Pancreas. 2014 Nov;43(8):1143-62. doi: 10.1097/MPA.0000000000000237.</citation>
    <PMID>25333398</PMID>
  </reference>
  <reference>
    <citation>Herzig KH, Purhonen AK, RÃ¤sÃ¤nen KM, Idziak J, Juvonen P, Phillps R, Walkowiak J. Fecal pancreatic elastase-1 levels in older individuals without known gastrointestinal diseases or diabetes mellitus. BMC Geriatr. 2011 Jan 25;11:4. doi: 10.1186/1471-2318-11-4.</citation>
    <PMID>21266058</PMID>
  </reference>
  <reference>
    <citation>Han S, Patel B, Min M, Bocelli L, Kheder J, Wachholtz A, Wassef W. Quality of life comparison between smokers and non-smokers with chronic pancreatitis. Pancreatology. 2018 Apr;18(3):269-274. doi: 10.1016/j.pan.2018.02.012. Epub 2018 Feb 26.</citation>
    <PMID>29500114</PMID>
  </reference>
  <reference>
    <citation>Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016 Apr 19;315(15):1624-45. doi: 10.1001/jama.2016.1464. Review.</citation>
    <PMID>26977696</PMID>
  </reference>
  <reference>
    <citation>Ferguson ND, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R, Brochard L, Brower R, Esteban A, Gattinoni L, Rhodes A, Slutsky AS, Vincent JL, Rubenfeld GD, Thompson BT, Ranieri VM. The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012 Oct;38(10):1573-82. Epub 2012 Aug 25. Erratum in: Intensive Care Med. 2012 Oct;38(10):1731-2.</citation>
    <PMID>22926653</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Eisen GM, Aabakken L, Baron TH, Hutter MM, Jacobson BC, Mergener K, Nemcek A Jr, Petersen BT, Petrini JL, Pike IM, Rabeneck L, Romagnuolo J, Vargo JJ. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc. 2010 Mar;71(3):446-54. doi: 10.1016/j.gie.2009.10.027.</citation>
    <PMID>20189503</PMID>
  </reference>
  <reference>
    <citation>Corley BT, Carroll RW, Hall RM, Weatherall M, Parry-Strong A, Krebs JD. Intermittent fasting in Type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med. 2018 May;35(5):588-594. doi: 10.1111/dme.13595. Epub 2018 Feb 27.</citation>
    <PMID>29405359</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>February 15, 2021</last_update_submitted>
  <last_update_submitted_qc>February 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospitals Cleveland Medical Center</investigator_affiliation>
    <investigator_full_name>Shaffer Mok</investigator_full_name>
    <investigator_title>Clinical Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>pancreatitis</keyword>
  <keyword>acute pancreatitis</keyword>
  <keyword>acute recurrent pancreatitis</keyword>
  <keyword>chronic pancreatitis</keyword>
  <keyword>fasting</keyword>
  <keyword>intermittent fasting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Pancreatitis, Chronic</mesh_term>
    <mesh_term>Pancreatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

